Last updated: June 27, 2026
Sanofi-Aventis U.S. LLC sued Aurobindo Pharma Limited in the District of Delaware under the Hatch-Waxman framework (1:22-cv-00141) in 2022, challenging Aurobindo’s proposed generic entry to a Sanofi branded product covered by listed Orange Book patents. The case’s procedural posture and the asserted patent set determine launch timing, potential settlement triggers, and likely design-around or carve-out strategy.
What is Sanofi-Aventis U.S. LLC v. Aurobindo Pharma Limited 1:22-cv-00141 about?
What court and docket details apply to 1:22-cv-00141
Case: Sanofi-Aventis U.S. LLC v. Aurobindo Pharma Limited
Docket: 1:22-cv-00141
Court: U.S. District Court, District of Delaware
Filed: 2022 (Hatch-Waxman litigation)
What Hatch-Waxman issues does the complaint typically raise
In Paragraph IV “infringement vs. invalidity” disputes, the patentee’s complaint generally asserts:
- The Orange Book–listed patents are infringed by the proposed generic product and/or its manufacturing and/or use.
- The defendant’s Paragraph IV notice fails to show non-infringement and fails to establish invalidity.
The defendant’s response typically pleads:
- Non-infringement (no literal infringement and no infringement under equivalents)
- Invalidity (commonly anticipation, obviousness, lack of enablement, and/or indefiniteness)
- Inequitable conduct (less common, but seen in brand-side strategies)
Which patents are asserted in Sanofi-Aventis v. Aurobindo 1:22-cv-00141?
No complete asserted-patent list is provided in the input.
Without the asserted patent numbers (or complaint exhibits), a complete infringement/validity analysis cannot be constructed from reliable case specifics.
What Orange Book status and Paragraph IV context drives this dispute?
How Orange Book listings shape the litigation posture
In Hatch-Waxman cases tied to an Orange Book listing, the litigation is anchored on the Orange Book patents assigned to:
- Drug substance (API) composition
- Drug product (formulation, polymorphs, salts, hydrates, solid-state forms)
- Methods of use (indication-specific claims, dosing regimens, patient selection)
- Manufacturing/process claims (if applicable)
The Orange Book patent status typically controls:
- Whether a Paragraph IV challenge was brought on expiry of a specific patent
- Whether a court may consider design-around arguments
- Whether any settlement has carve-outs tied to specific claim categories (e.g., process only vs. use only)
Practical effect for generic entry planning
The defendant’s generic launch is generally blocked until:
- a relevant asserted patent expires, or
- the asserted patent is held invalid/not infringed, or
- the parties settle with an agreed entry date and any FDA-specific implementation.
What are the infringement theories likely used against Aurobindo in 1:22-cv-00141?
Product infringement vs. method-of-use infringement
If the asserted claims are:
- Composition/formulation claims: infringement analysis focuses on whether Aurobindo’s generic matches claim limitations for salt/form, polymorph, excipients, particle size, dissolution profile, or solid-state properties.
- Method-of-use claims: infringement analysis focuses on whether the proposed label and recommended regimen induce infringement under the asserted claims.
Manufacturing and equivalence risks
If process patents are asserted, infringement turns on whether Aurobindo’s manufacturing method meets the claimed steps, including impurities, temperature/time windows, crystallization controls, and scale-up constraints.
Equivalence arguments depend on:
- prosecution history estoppel (if present)
- claim scope at issuance
- prior art and objective indicia of non-obviousness
What validity and non-infringement defenses are typical in this case type?
Anticipation and obviousness frameworks
Common invalidity contentions include:
- Anticipation: a single prior art reference discloses every claim limitation.
- Obviousness: a combination of references renders the claim obvious to a skilled artisan.
Courts often focus on:
- claim construction
- whether prior art combinations require “routine optimization” vs. non-routine modifications
- secondary considerations, when properly evidenced
Indefiniteness, enablement, and written description
If the asserted patents are formulation or solid-state:
- written description and enablement disputes often revolve around whether the specification supports the scope of polymorph/particle-size/disclosure breadth
If the asserted claims are method-of-use:
- enablement and definiteness disputes may focus on whether the specification teaches the claimed dosing regimen and patient selection without undue experimentation.
How does this litigation affect generic launch timing for Aurobindo?
What a court win would enable
If Aurobindo prevails on:
- non-infringement and/or invalidity of the asserted patents, then FDA approval can result in launch after any exclusivity protections (if any) tied to the reference product and after regulatory readiness.
What a brand win would preserve
If Sanofi prevails:
- launch is blocked until the asserted patents expire or the case resolves via appeal or settlement.
What settlement outcomes typically occur in Sanofi v. generic Hatch-Waxman cases?
Common settlement structures
Hatch-Waxman settlements often include:
- a “launch date” covenant tied to patent expiry
- covenant not to sue for certain strengths/dosage forms/indications
- agreed labeling design changes (where method-of-use claims are implicated)
- optional dismissal of certain defendants or claims
Business implications
Settlements reduce:
- litigation cost and uncertainty
- time-to-market unpredictability
- risk of injunction threats (rarely granted if the case resolves before injunction posture, but still relevant depending on timing)
What is the current status of 1:22-cv-00141 and what procedural events matter?
No procedural status (e.g., dismissal, summary judgment, Markman order, trial, settlement) is provided in the input.
A litigation-status analysis requires docket-specific events and dates.
How strong is Sanofi’s patent estate in this dispute versus Aurobindo’s invalidity posture?
No asserted patent numbers or claim summaries are provided in the input.
A strength comparison requires:
- claim chart inputs tied to asserted independent claims
- file histories (for prosecution history estoppel and disclaimer)
- litigation positions (construction outcomes at Markman)
Key takeaways
- The case is a Hatch-Waxman patent infringement dispute filed by Sanofi against Aurobindo in the District of Delaware, docket 1:22-cv-00141, in 2022.
- The legal impact on launch timing depends on the specific Orange Book patents asserted and the resulting rulings on infringement and validity.
- A complete claim-by-claim litigation and patent-strength analysis cannot be produced from the provided input because the asserted patent list, claim categories, and docket status are not included.
FAQs
1) What patents did Sanofi assert in 1:22-cv-00141?
The input does not include asserted patent numbers.
2) Was this an ANDA Paragraph IV case, and what triggers the filing?
The case is of the Hatch-Waxman type, but the input provides no Orange Book/notice identifiers.
3) What claim types usually drive Sanofi v. Aurobindo brand-protecting disputes?
Typically composition/formulation, method-of-use, and sometimes process claims, but the specific claim categories are not provided.
4) What procedural milestones usually determine summary-judgment or trial posture in Delaware Hatch-Waxman cases?
Markman claim construction, Daubert challenges, and dispositive motions based on infringement/invalidity.
5) How does an eventual settlement typically affect FDA labeling and launch design?
Settlements often include date and labeling carve-outs aligned to asserted claims, but the input does not include this case’s settlement terms.
References (APA)
- Sanofi-Aventis U.S. LLC v. Aurobindo Pharma Limited, No. 1:22-cv-00141 (D. Del. 2022).
